CMPS COMPASS Pathways plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1816590 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY14.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-296.5%
ROA-68.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets72.6%
Debt / equity0.36x
Current ratio1.50x
Interest coverage-35.36x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $118.44M | $119.04M |
| SG&A expense | $60.60M | $59.17M |
| Operating income | -$179.04M | -$178.21M |
| Interest expense | $4.52M | $4.48M |
| Pretax income | -$290.33M | -$153.53M |
| Income tax | -$2.47M | $1.59M |
| Net income | -$287.86M | -$155.12M |
| EBITDA | -$178.82M | -$177.97M |
| EPS (basic) | -3.08 | -2.30 |
| EPS (diluted) | -3.08 | -2.30 |
| Weighted avg. shares (diluted) | 93.50M | 67.48M |
| Balance sheet | ||
| Cash & equivalents | $149.61M | $165.47M |
| Current assets | $191.49M | $201.29M |
| PP&E, net | — | $189,000 |
| Total assets | $210.35M | $213.67M |
| Current liabilities | $247.79M | $34.02M |
| Short-term debt | $17.52M | $5.51M |
| Long-term debt | $14.11M | $24.65M |
| Total debt | $31.63M | $30.16M |
| Total liabilities | $263.20M | $58.97M |
| Shareholders' equity | -$52.85M | $154.69M |
| Net debt | -$117.97M | -$135.31M |
| Shares outstanding | 96.09M | 68.55M |
| Cash flow statement | ||
| Operating cash flow | -$157.24M | -$119.19M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$119.19M |
| Investing cash flow | — | $0 |
| Financing cash flow | $140.71M | $63.82M |
| Depreciation & amortization | $216,000 | $233,000 |
| Stock-based compensation | $13.59M | $19.52M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.